20 related articles for article (PubMed ID: 31761713)
1. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
[TBL] [Abstract][Full Text] [Related]
2. The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.
Schönefeldt S; Wais T; Herling M; Mustjoki S; Bekiaris V; Moriggl R; Neubauer HA
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944832
[TBL] [Abstract][Full Text] [Related]
3. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A; Haverkos BM; Zain J; Radhakrishnan R; Lechowicz MJ; Devata S; Korman NJ; Pinter-Brown L; Oki Y; Barde PJ; Nair A; Routhu KV; Viswanadha S; Vakkalanka S; Iyer SP
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824175
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
5. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Flinn IW; O'Brien S; Kahl B; Patel M; Oki Y; Foss FF; Porcu P; Jones J; Burger JA; Jain N; Kelly VM; Allen K; Douglas M; Sweeney J; Kelly P; Horwitz S
Blood; 2018 Feb; 131(8):877-887. PubMed ID: 29191916
[TBL] [Abstract][Full Text] [Related]
6. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Flinn IW; Patel M; Oki Y; Horwitz S; Foss FF; Allen K; Douglas M; Stern H; Sweeney J; Kharidia J; Kelly P; Kelly VM; Kahl B
Am J Hematol; 2018 Nov; 93(11):1311-1317. PubMed ID: 30033575
[TBL] [Abstract][Full Text] [Related]
7. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
8. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
9. A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Carlo-Stella C; Delarue R; Scarfo L; Barde PJ; Nair A; Locatelli SL; Morello L; Magagnoli M; Vakkalanka S; Viswanadha S; Ferreri AJM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):78-86. PubMed ID: 31761713
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]